High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.
JSON
Karimi M, Nilsson C, Dimitriou M, Jansson M, Matsson H, Unneberg P, Lehmann S, Kere J, Hellström-Lindberg E
Haematologica 100 (6) e223-e225 [2015-06-00; online 2015-03-15]
Mutation Analysis Facility (MAF)
NGI Stockholm (Genomics Applications)
NGI Stockholm (Genomics Production)
National Genomics Infrastructure
PubMed 25769547
DOI 10.3324/haematol.2014.118034
Crossref 10.3324/haematol.2014.118034
pii: haematol.2014.118034
pmc: PMC4450634